Featured Press Releases

Aadi Bioscience reports Q3 2024 financial results and updates on corporate progress

Aadi Bioscience reports Q3 2024 financial results and updates on corporate progress

Abzena Launches LabZient™, an Analytical Platform to Expedite the Path to IND for Antibodies

Abzena Launches LabZient™, an Analytical Platform to Expedite the Path to IND for Antibodies

  • 08 Feb 2024

Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, has...

Promega introduces the GloMax® Galaxy Bioluminescence Imager to illuminate protein dynamics in real time

Promega introduces the GloMax® Galaxy Bioluminescence Imager to illuminate protein dynamics in real time

NLS Pharmaceutics and Kadimastem announce a $500,000 initial closing of a $1 million fundraising, with shares priced at $3.10, a 48% premium over the January 6, 2025 market price

NLS Pharmaceutics and Kadimastem announce a $500,000 initial closing of a $1 million fundraising, with shares priced at $3.10, a 48% premium over the January 6, 2025 market price

CRENESSITY® lowers glucocorticoid doses while maintaining androgen control in adults with classic congenital adrenal hyperplasia

CRENESSITY® lowers glucocorticoid doses while maintaining androgen control in adults with classic congenital adrenal hyperplasia

TrueMed Selected by a Global Top-10 Pharmaceutical Company to Protect Three High-Volume Drug Brands Against Counterfeit Threats

TrueMed Selected by a Global Top-10 Pharmaceutical Company to Protect Three High-Volume Drug Brands Against Counterfeit Threats

Virax Biolabs CEO James Foster Updates Shareholders Following the Fiscal 2026 Annual Report and Commercial Supply Agreement with Fosun Diagnostics

Virax Biolabs CEO James Foster Updates Shareholders Following the Fiscal 2026 Annual Report and Commercial Supply Agreement with Fosun Diagnostics

  • Virax BioLabs Group Limited
  • 16 Jul 2026
Children

Children's Hospital of Philadelphia Initiative Substantially Increases Naloxone Co-Prescribing When Prescribing Outpatient Opioids

  • Children's Hospital of Philadelphia
  • 16 Jul 2026
Hologic’s Aptima® HPV Test Receives Expanded CE-IVDR Mark to Include Self-Collected Samples for Cervical Cancer Screening

Hologic’s Aptima® HPV Test Receives Expanded CE-IVDR Mark to Include Self-Collected Samples for Cervical Cancer Screening

  • Hologic, Inc.
  • 14 Jul 2026
Erbitux® (cetuximab) in Combination with Encorafenib and FOLFOX Approved by the European Commission as a First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

Erbitux® (cetuximab) in Combination with Encorafenib and FOLFOX Approved by the European Commission as a First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

  • Merck
  • 14 Jul 2026
BioMarin

BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia Accepted by the U.S. Food and Drug Administration

  • BioMarin Pharmaceutical Inc.
  • 13 Jul 2026
FDA Approves Expanded Indication for Octapharma USA

FDA Approves Expanded Indication for Octapharma USA's wilate® for Prophylaxis of von Willebrand Disease in Children Younger Than 6 Years

  • Octapharma
  • 10 Jul 2026
The Digital Pharma Advances Conference 2026

Most Popular
July   2026
M T W T F S S
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.